Skip to main content
. 2015 Sep 7;5(9):e008597. doi: 10.1136/bmjopen-2015-008597

Figure 1.

Figure 1

Study participation (IBD, inflammatory bowel disease; TNF, tumour necrosis factor). *Case-finding algorithm criteria are met with ≥2 claims for CD:555.xx or UC:556.xx. ***Anti-TNF contraindications are advanced CHF and malignancies as defined in online supplementary appendix 1. ***Prevalent anti-TNF users were already receiving therapy during the baseline period.